Vergne-Salle, Pascale <br/><br/>
A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia.  [electronic resource] 

 -  European journal of pain (London, England)  May 2011 
 - 509-14 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-2149 
<br/><br/><label>Standard No.: </label>10.1016/j.ejpain.2010.09.013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Chronic Disease<br/>Double-Blind Method<br/>Fibromyalgia--drug therapy<br/>Follow-Up Studies<br/>Humans<br/>Indoles--administration & dosage<br/>Injections, Intravenous<br/>Middle Aged<br/>Pain--drug therapy<br/>Placebos<br/>Prospective Studies<br/>Quality of Life<br/>Quinolizines--administration & dosage<br/>Serotonin 5-HT3 Receptor Antagonists--administration & dosage<br/>Treatment Outcome<br/>Young Adult